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ABStrACt 
Introduction: Patients treated with nitrogen-containing bisphosphonates, such as zoledronic acid (ZA), have frequently shown oral 
bone exposure areas, termed osteonecrosis. In addition, these patients may also present low repair and regeneration potential, mainly 
after tooth extractions. These side-effects caused by bisphosphonates may be due to their inhibitory effects on oral mucosa and local bone 
cells. Objective: To evaluate the effects of ZA on the mineralization capacity of cultured osteoblasts. Materials and methods: Human 
immortalized osteoblasts (SaOs-2) were grown in plain culture medium (Dulbecco’s Modified Eagle Medium [DMEM] + 10% fetal bovine 
serum [FBS]) in wells of 24-well plates. After 48-hour incubation, the plain DMEM was replaced by a solution with ZA at 5 µM which was 
maintained in contact with cells for seven, 14 or 21 days. After these periods, cells were evaluated regarding alkaline phosphatase (ALP) 
activity and mineral nodule formation (alizarin red). Data were statistically analyzed by Mann-Whitney test, at 5% of significance level. 
Results: ZA caused significant reduction on ALP activity and mineral nodules formation by cultured osteoblasts in all evaluated periods 
(p < 0.05). Conclusion: These data indicate that ZA causes inhibition on the osteogenic phenotype of cultured human osteoblasts, which, 
in turn, may reduce bone repair in patients subjected to ZA therapy.
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introDuCtion
Bisphosphonates are indicated for the treatment of diseases 
characterized by intense bone resorption. Their main mechanism 
of action is inhibition of osteoclast maturation and activity. The use 
of these drugs has been linked to the development of osteonecrosis 
in the oral cavity, a condition that seems to be associated with the 
reduction of tissue repair capacity(2, 3).
Several studies demonstrate that bisphosphonates present 
inhibitory effect on different cell types, like osteoblast and epithelial 
cells, what may explain, at least partially, the development of 
osteonecrosis(1, 11, 14).
The zoledronic acid (ZA) is known as a potent bisphosphonate, 
particularly due to its greater capacity of adherence to the bone 
tissue(9). It is administered intravenously, with the frequency of use 
varying according to the disease to be treated and the established 
therapy(9). Patients in treatment with this kind of bisphosphonate 
have presented higher risk for the development of osteonecrosis, 
what is directly related to the dose and the frequency of use(9).
The etiopathogenesis of bisphosphonate-induced osteonecrosis 
has been associated with local traumas, like tooth extractions(6). 
Besides, individuals treated with ZA also present low capacity for 
tissue repair and regeneration. This fact would explain the delay 
in the repair of bone and mucous tissue in patients treated with 
this drug(3,10).
The low repair capacity after tooth extractions observed 
in patients treated with bisphosphonates may be related to a 
reduction in mineralization activity by local osteoblasts. Therefore, 
the objective of this study was to assess the mineralization capacity 




An immortalized human osteoblast cell line was used 
(SaOs-2 ATCC HTB-85). The cells, grown in plain culture medium 
(Dulbecco’s Modified Eagle Medium [DMEM], GIBCO, Grand 
Island, NY, USA), containing antibiotics (100 IU/ml penicillin and 
100 μg/ml streptomycin – GIBCO) and 10% fetal bovine serum 
([FBS] – GIBCO), were kept in incubation at 37ºC with 5% CO
2
, 
until the obtainment of the necessary number for the conduction 
of the experiment. 
Thus, cells were seeded in wells of 24-well plates (Techno 
Plastic Products AG, Trasadingen, Switzerland), for 48 hours. Next, 
the complete DMEM was replaced by an osteogenic differentiation 
medium, characterized by the presence of ß-glycerophosphate 
and ascorbic acid (Sima-Aldrich, St. Louis, MO, USA), but without 
the addition of FBS. Five µM ZA (Novartis, São Paulo, SP, Brazil) 
were added to this new medium, which was put in contact with 
cells during seven, 14 and 21 days. The osteogenic medium was 
replaced every three days, with new addition of the drug, in the 
same concentration.
Alkaline phosphatase (ALP) activity
Cells exposure to the solution of ZA in the defined periods was 
followed by the assessment of alkaline phosphatase (ALP) activity, 
which is highly expressed by osteoblasts and takes part in the 
mineralization of the bone matrix. This assessment was conducted 
as described by Oliveira et al.(7). In general, the used protocol 
characterizes as a colorimetric endpoint assay, which produces, 
by means of a dephosphorylation reaction of thymolphthalein, a 
bluish solution, which may come in different shades according 
to the activity of the ALP enzyme present in the solution. This 
enzyme activity was determined spectrophotometrically (Termo 
Plate, Nanshan District, Shenzhen, China) by absorbance reading 
of the 590-nm solution. Its concentration is determined from a 
standard curve prepared according to the analysis of the known 
ALP concentrations. 
Formation of mineralized nodules (alizarin red)
Osteoblast capacity to form mineralized nodules in culture 
was accomplished according to Idris et al.(5). This assay reflects 
the capacity of these cells to form an organized and mineralized 
matrix, typical of bone tissue in the process of repair.
For the implementation of this protocol, cells were cultured 
in osteogenic differentiation medium during the experimental 
process (seven, 14 and 21 days). This medium provides the 
necessary substrates for the synthesis and deposition of components 
of the bone matrix by osteoblasts in culture.
After fixation in etanol 70% at 4ºC and staining with alizarin 
red (40 mM, pH 4.2) (Sigma-Aldrich, St. Louis, MO, USA), it was 
possible to visualize the formation of mineralized nodules under 
an optical microscope (Olympus BX51, Miami, FL, USA), attached 
to a camera (Olympus C5060, Miami, FL, USA), for a qualitative 
analysis.
Part of the samples was subjected to quantitative analysis 
of mineralized nodule formation, which consists of the 
dissolution of the nodules in a cetylpyridinium chloride solution 
(Sigma-Aldrich). This dissolution results in the formation of a 
homogeneous solution, which is subjected to a spectrophotometric 
(Termo Plate) analysis of absorbance (562 nm).
Statistical analysis 
Data on ALP and formation of mineralized nodules were 
assessed for normality. As these data did not present normal 
distribution, Mann-Whitney test was used, considering a 
significance level of 5%.
rESuLtS
Data on the ALP activity by osteoblasts (SaOs-2), according to 
treatment and assessment period, are presented on Table 1.
tABLE 1 –  Alkaline phosphatase activity (%) of SaOs-2 cells,  





7 *101.51 (92.81-108.74) a A 37.37 (32.90-46.74) b A
14 99.04 (95.87-105.05) a A 16.86 (16.62-17.33) b B
21 101.24 (94.55-103.05) a A 19.51 (18.76-20.69) b B
Values are medians (25th percentile-75th percentile), n = 8.
*Lower case letters allow the comparison in the lines; capital letters, in the columns. 
Values with the same letters do not differ statistically (Mann-Whitney, p > 0.05).
For the period of seven days, the group treated with ZA presented 
reduction of 64% in the ALP activity values when compared to the 
control group with no treatment (p = 0.001). In later periods, of 
14 and 21 days, the same pattern of cellular response was observed, 
with an 82% reduction of ALP activity (p = 0.001) for both groups.
There were no differences in ALP activity for the control group 
in the three assessment periods (p > 0.05). For the group treated 
Fernanda Gonçalves Basso; Ana Paula Silveira Turrioni; Josimeri Hebling; Carlos Alberto de Souza Costa
370
with ZA, the period of seven days presented the highest ALP values 
when compared to the other periods, with significant statistical 
difference (p < 0.05). The periods of 14 and 21 days did not differ 
from each other (p > 0.05).
The data on mineralized nodule formation by SaOs-2 cells, 
according to treatment and assessment period, are presented on 
Table 2.
was determined by the significant reduction of ALP activity by 
osteoblasts, which had their capacity to form mineralized nodules 
dramatically reduced. Within the limitations of the present study, 
one may suggest that these scientific data observed in cultured 
human osteoblasts could explain, at least partially, Allen’s(3) 
results. He demonstrated delay in bone repair in patients treated 
with this medicine.
Orris et al.(8) also studied the activity of human osteoblasts in 
culture, however the concentrations of ZA used by the authors were 
10 nm, 100 nm, 1 μM and 100 μM, which did not correspond to 
those found in the oral cavity of patients treated with this kind of 
bisphosphonate(12). Despite the methodological differences, Orris 
et al.(8) found results similar to those in this study, particularly 
related to the significant reduction in ALP and mineralized nodule 
production, which presented as dose- and time-dependent. Besides, 
previous studies demonstrated that ZA also promotes significant 
inhibition of the expression of type I(6, 13) collagen, main organic 
component of the bone matrix, what directly interferes in the 
process of tissue repair(4).
By knowing the possible undesirable side-effects of ZA on the 
metabolism of different cell types and the resulting interference 
of this drug in the repair and regeneration process, perhaps other 
types of bisphosphonates might be used more safely. However, Idris 
et al.(5) showed that other aminobisphosphonates, despite seeming 
less potent than ZA, also caused important negative effects on the 
activity of osteoblasts in vitro, as it was demonstrated in this and 
in previous studies(6, 8, 12, 13). 
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tABLE 2 –  Formation of mineralized nodules (%)  





7 *98.42 (96.40-105.69) a C 13.39 (11.58-21.23) b C
14 110.04 (107.40-114.53) a B 27.09 (18.91-37.08) b B
21 107.26 (106.09-120.89) a A 43.95 (39.17-47.96) b A
Values are medians (25th percentile-75th percentile), n = 8. 
*Lower case letters allow the comparison in the lines; capital letters, in the columns. 
Values with the same letters do not differ statistically (Mann-Whitney, p > 0.05).
Cells treatment with ZA decreased mineralized nodule 
formation. In the period of seven days, the treated group suffered 
an 85% reduction on the values of mineralized nodule formation 
when compared to the control group (p = 0.001). In the periods 
of 14 and 21 days, the reductions were 83% and 63%, respectively 
(p = 0.001).
When comparing the different assessment periods, the period 
of 21 days presented the highest values in nodule formation, 
followed by the periods of 14 and seven days, with a statistical 
difference among all of them (p < 0.05).
DiSCuSSion
The results of this study show that human osteoblasts exposed 
to ZA presented a significant reduction in the capacity to produce 
components of matrix formation and mineralization. This 
rESuMo 
Introdução: Pacientes em tratamento com bisfosfonatos, sobretudo com os nitrogenados, como o ácido zoledrônico (AZ), têm 
apresentado áreas de exposição de tecido ósseo na cavidade oral, caracterizadas como osteonecrose. Essas áreas apresentam 
limitada capacidade de reparo, principalmente após exodontias. Esses efeitos podem ser resultado do efeito inibitório causado por 
esse tipo de medicamento sobre as células da mucosa e do tecido ósseo local. Objetivo: Avaliar o efeito do AZ sobre a capacidade 
de mineralização de osteoblastos in vitro. Materiais e métodos: Foi utilizada uma linhagem celular de osteoblastos humanos 
(SaOs-2). As células foram cultivadas em meio de cultura completo (Dulbecco’s Modified Eagle Medium [DMEM] + 10% de soro 
fetal bovino [SFB]). Após 48 horas de incubação, o DMEM completo foi substituído por um novo DMEM sem SFB, ao qual foram 
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adicionados 5 µM de AZ. Essa solução foi mantida em contato com as células por sete, 14 ou 21 dias. Após esse período, as células 
foram avaliadas quanto à atividade de fosfatase alcalina (ALP) e à produção de nódulos de mineralização (alizarin red). Os dados 
foram submetidos ao teste estatístico de Mann-Whitney, considerando nível de significância de 5%. Resultados: A exposição das 
células ao AZ causou redução significativa na atividade de ALP e na formação de nódulos mineralizados em todos os períodos 
avaliados (p < 0,05). Conclusão: Esses resultados revelam que o AZ causa alteração inibitória no fenótipo osteogênico das células 
humanas em cultura, o que pode reduzir a capacidade de reparo do tecido ósseo após o contato com esse tipo de medicamento.
  
Unitermos: osteonecrose; reparo; mineralização; osteoblastos.
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